Company
ABOUT TRULIVE MEDICAL
About Trulive
Jiangsu Trulive Medtech Co., Ltd. was founded in Nantong, Jiangsu Province in 2019. As an innovative medical device enterprise specializing in cardiovascular diseases in China, it integrates R&D, manufacturing, sales and technical services. Devoted to the cardiovascular health sector, the company strives to break the monopoly of imported technologies and develop high-quality domestic cardiovascular diagnosis and treatment devices.
Boasting well-rounded business layout and clear organizational structure, the company has gradually built up a large-scale industrial system. It owns three wholly-owned subsidiaries: Anhui Yipeng Medtech Co., Ltd., Jiangsu Poly Medtech Co., Ltd. and Hangzhou Dawneo Medical Technology Co., Ltd. Meanwhile, Shanghai Trulive Medtech Co., Ltd. has been set up to focus on R&D and Commercialization. Leveraging Shanghai's high-end talents and technical resources, the company concentrates on integrating cutting-edge medical technologies and accelerating product iteration and upgrading.
Its product portfolio covers structural heart valves and coronary and peripheral vessels, delivering one-stop therapeutic solutions for cardiovascular diseases. Core product pipelines feature a host of innovative interventional products such as DeepQuake® intravascular lithotripsy, NeoNova® mitral transcatheter edge-to-edge repair system and NeoBlazar® tricuspid transcatheter edge-to-edge repair system.
The enterprise brings together seasoned R&D and management professionals from the industry and holds over three hundred independent intellectual property rights. It has received many authoritative honors including Provincial Potential Unicorn Enterprise and Innovative SME. Going forward, building on its multi-location industrial and R&D footprint, Trulive Medical will adhere to independent innovation, further advance in the high-end medical sector, develop cost-effective domestic medical devices, and provide safe, high-quality and affordable cardiovascular disease treatment solutions for patients at home and abroad.
Milestones
Development History
From establishment to global layout, every step carries the commitment to life and health
Company Founded
In 2019, Jiangsu Trulive Medtech Co., Ltd. was established.
Clinical Research Started
In 2022, pre-marketing clinical research for NeoBlazar was initiated.
Jiangsu Potential Unicorn Enterprise Recognition
In 2023, the company was recognized as a Jiangsu potential unicorn enterprise.
Product Approved
In 2024, DeepQuake – Intravascular Lithotripsy catheter obtained NMPA product license.
Clinical Enrollment
In 2024, TruGamma for tricuspid valve replacement completed its first clinical enrollment.
Product Approved
In 2025, NeoNova, Mitral Transcatheter Edge-to-Edge Repair system was launched in China.
Product Approved
In March 2026, Paflash pulmonary artery thrombus removal system was marketed.
Product Approved
In July 2026, NeoBlazar Tricuspid Transcatheter Edge-to-Edge Repair system was unveiled.
Core Values
Core Advantages
Driven by technological innovation, guided by patient needs
Patient-Centric
Helping humanity fight cardiovascular diseases, providing patients with safer and more effective treatment solutions.
Innovative Solutions
Developing and providing innovative diagnosis and treatment solutions, advancing medical technology.
Reliable Partnership
Building trust with partners and patients, creating a win-win ecosystem.
Continuous Innovation
Breaking boundaries, advancing medical progress, and continuously investing in R&D innovation.
Year Founded
Patent Applications
Top Hospitals Covered
Current Employees
Our Mission
Our Mission
Patient-Centric
Helping humanity fight cardiovascular diseases
Innovative Solutions
Developing innovative diagnosis and treatment solutions
Reliable Partnership
Building trust with partners and patients, creating a win-win ecosystem
Continuous Innovation
Breaking boundaries, advancing medical progress